Inflammation

Inflammation
An allergic reaction to cefaclor has led to inflammation of the skin on the foot. The cardinal signs of inflammation include: pain, heat, redness, swelling, and loss of function. Some of these indicators can be seen here.
Specialty	Immunology, rheumatology
Symptoms	Heat, pain, redness, swelling
Complications	Asthma, pneumonia, autoimmune diseases
Duration	Acute: few days Chronic: up to many months, or years
Causes	Infection, physical injury, autoimmune disorder

Inflammation (from Latin : inflammatio ) is part of the biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. ^{[1] [2]} The five cardinal signs are heat, pain, redness, swelling, and loss of function (Latin calor, dolor, rubor, tumor, and functio laesa).

Inflammation is a generic response, and therefore is considered a mechanism of innate immunity, whereas adaptive immunity is specific to each pathogen. ^[3]

Inflammation is a protective response involving immune cells, blood vessels, and molecular mediators. The function of inflammation is to eliminate the initial cause of cell injury, clear out damaged cells and tissues, and initiate tissue repair. Too little inflammation could lead to progressive tissue destruction by the harmful stimulus (e.g. bacteria) and compromise the survival of the organism. However inflammation can also have negative effects. ^[4] Too much inflammation, in the form of chronic inflammation, is associated with various diseases, such as hay fever, periodontal disease, atherosclerosis, and osteoarthritis.

Inflammation can be classified as acute or chronic. Acute inflammation is the initial response of the body to harmful stimuli, and is achieved by the increased movement of plasma and leukocytes (in particular granulocytes) from the blood into the injured tissues. A series of biochemical events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells in the injured tissue. Prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells present at the site of inflammation, such as mononuclear cells, and involves simultaneous destruction and healing of the tissue.

Inflammation has also been classified as Type 1 and Type 2 based on the type of cytokines and helper T cells (Th1 and Th2) involved. ^[5]

Meaning

The earliest known reference for the term inflammation is around the early 15th century. The word root comes from Old French inflammation around the 14th century, which then comes from Latin inflammatio or inflammationem. Literally, the term relates to the word "flame", as the property of being "set on fire" or "to burn". ^[6]

The term inflammation is not a synonym for infection. Infection describes the interaction between the action of microbial invasion and the reaction of the body's inflammatory response—the two components are considered together in discussion of infection, and the word is used to imply a microbial invasive cause for the observed inflammatory reaction. Inflammation, on the other hand, describes just the body's immunovascular response, regardless of cause. But, because the two are often correlated, words ending in the suffix -itis (which means inflammation) are sometimes informally described as referring to infection: for example, the word urethritis strictly means only "urethral inflammation", but clinical health care providers usually discuss urethritis as a urethral infection because urethral microbial invasion is the most common cause of urethritis. However, the inflammation–infection distinction is crucial in situations in pathology and medical diagnosis that involve inflammation that is not driven by microbial invasion, such as cases of atherosclerosis, trauma, ischemia, and autoimmune diseases (including type III hypersensitivity).

Causes

Physical:

• Burns ^[7]
• Frostbite
• Physical injury, blunt or penetrating ^[8]
• Foreign bodies, including splinters, dirt and debris
• Trauma ^[7]
• Ionizing radiation

Biological:

• Infection by pathogens ^[7]
• Immune reactions due to hypersensitivity
• Stress

Chemical: ^[7]

• Chemical irritants
• Toxins
• Alcohol

Psychological:

• Excitement ^[9]

Types

See also: List of inflammatory disorders and List of types of inflammation by location

Appendicitis Bursitis Colitis Cystitis Dermatitis Epididymitis Encephalitis Gingivitis Meningitis Myelitis Myocarditis Nephritis Neuritis Pancreatitis Periodontitis

Pharyngitis Phlebitis Prostatitis RSD/CRPS Rhinitis Sinusitis Tendonitis Tonsillitis Urethritis Vasculitis Vaginitis

Comparison between acute and chronic inflammation:

	Acute	Chronic
Causative agent	Bacterial pathogens, injured tissues	Persistent acute inflammation due to non-degradable pathogens, viral infection, persistent foreign bodies, or autoimmune reactions
Major cells involved	neutrophils (primarily), basophils (inflammatory response), and eosinophils (response to helminth worms and parasites), mononuclear cells (monocytes, macrophages)	Mononuclear cells (monocytes, macrophages, lymphocytes, plasma cells), fibroblasts
Primary mediators	Vasoactive amines, eicosanoids	IFN-γ and other cytokines, growth factors, reactive oxygen species, hydrolytic enzymes
Onset	Immediate	Delayed
Duration	Few days	Up to many months, or years
Outcomes	Resolution, abscess formation, chronic inflammation	Tissue destruction, fibrosis, necrosis

Acute

Acute inflammation is a short-term process, usually appearing within a few minutes or hours and begins to cease upon the removal of the injurious stimulus. ^[10] It involves a coordinated and systemic mobilization response locally of various immune, endocrine and neurological mediators of acute inflammation. In a normal healthy response, it becomes activated, clears the pathogen and begins a repair process and then ceases. ^[11]

Acute inflammation occurs immediately upon injury, lasting only a few days. ^[12] Cytokines and chemokines promote the migration of neutrophils and macrophages to the site of inflammation. ^[12] Pathogens, allergens, toxins, burns, and frostbite are some of the typical causes of acute inflammation. ^[12] Toll-like receptors (TLRs) recognize microbial pathogens. ^[12] Acute inflammation can be a defensive mechanism to protect tissues against injury. ^[12] Inflammation lasting 2–6 weeks is designated subacute inflammation. ^{[12] [13]}

Cardinal signs

The classic signs and symptoms of acute inflammation: ^[a]

English	Latin
Redness	Rubor
Swelling	Tumor
Heat	Calor
Pain	Dolor
Loss of function	Functio laesa [b]

Inflammation is characterized by five cardinal signs, ^{[16] [17]} (the traditional names of which come from Latin):

• Dolor (pain)
• Calor (heat)
• Rubor (redness)
• Tumor (swelling)
• Functio laesa (loss of function) ^[18]

The first four (classical signs) were described by Celsus (c. 30 BC–38 AD). ^[19]

Pain is due to the release of chemicals such as bradykinin and histamine that stimulate nerve endings. ^[16] (Acute inflammation of the lung (usually in response to pneumonia) does not cause pain unless the inflammation involves the parietal pleura, which does have pain-sensitive nerve endings. ^[16] ) Heat and redness are due to increased blood flow at body core temperature to the inflamed site. Swelling is caused by accumulation of fluid.

Loss of function

The fifth sign, loss of function, is believed to have been added later by Galen, ^[20] Thomas Sydenham ^[21] or Rudolf Virchow. ^{[10] [16] [17]} Examples of loss of function include pain that inhibits mobility, severe swelling that prevents movement, having a worse sense of smell during a cold, or having difficulty breathing when bronchitis is present. ^{[22] [23]} Loss of function has multiple causes. ^[16]

Acute process

A flowchart depicting the events of acute inflammation.

Micrograph showing granulation tissue. H&E stain.

The process of acute inflammation is initiated by resident immune cells already present in the involved tissue, mainly resident macrophages, dendritic cells, histiocytes, Kupffer cells and mast cells. These cells possess surface receptors known as pattern recognition receptors (PRRs), which recognize (i.e., bind) two subclasses of molecules: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). PAMPs are compounds that are associated with various pathogens, but which are distinguishable from host molecules. DAMPs are compounds that are associated with host-related injury and cell damage.

At the onset of an infection, burn, or other injuries, these cells undergo activation (one of the PRRs recognize a PAMP or DAMP) and release inflammatory mediators responsible for the clinical signs of inflammation. Vasodilation and its resulting increased blood flow causes the redness (rubor) and increased heat (calor). Increased permeability of the blood vessels results in an exudation (leakage) of plasma proteins and fluid into the tissue (edema), which manifests itself as swelling (tumor). Some of the released mediators such as bradykinin increase the sensitivity to pain (hyperalgesia, dolor). The mediator molecules also alter the blood vessels to permit the migration of leukocytes, mainly neutrophils and macrophages, to flow out of the blood vessels (extravasation) and into the tissue. The neutrophils migrate along a chemotactic gradient created by the local cells to reach the site of injury. ^[10] The loss of function (functio laesa) is probably the result of a neurological reflex in response to pain.

In addition to cell-derived mediators, several acellular biochemical cascade systems—consisting of preformed plasma proteins—act in parallel to initiate and propagate the inflammatory response. These include the complement system activated by bacteria and the coagulation and fibrinolysis systems activated by necrosis (e.g., burn, trauma). ^[10]

Acute inflammation may be regarded as the first line of defense against injury. Acute inflammatory response requires constant stimulation to be sustained. Inflammatory mediators are short-lived and are quickly degraded in the tissue. Hence, acute inflammation begins to cease once the stimulus has been removed. ^[10]

Chronic

Main article: Chronic inflammation

Chronic inflammation is inflammation that lasts for months or years. ^[13] Macrophages, lymphocytes, and plasma cells predominate in chronic inflammation, in contrast to the neutrophils that predominate in acute inflammation. ^[13] Diabetes, cardiovascular disease, allergies, and chronic obstructive pulmonary disease (COPD) are examples of diseases mediated by chronic inflammation. ^[13] Obesity, smoking, stress and insufficient diet are some of the factors that promote chronic inflammation. ^[13] A 2014 study reported that 60% of Americans had at least one chronic inflammatory condition, and 42% had more than one. ^[13]

Cardinal signs

Common signs and symptoms that develop during chronic inflammation are: ^[13]

• Body pain, arthralgia, myalgia
• Chronic fatigue and insomnia
• Depression, anxiety and mood disorders
• Gastrointestinal complications such as constipation, diarrhea, and acid reflux
• Weight gain or loss
• Frequent infections

Vascular component

Vasodilation and increased permeability

As defined, acute inflammation is an immunovascular response to inflammatory stimuli, which can include infection or trauma. ^{[25] [26]} This means acute inflammation can be broadly divided into a vascular phase that occurs first, followed by a cellular phase involving immune cells (more specifically myeloid granulocytes in the acute setting). ^[25] The vascular component of acute inflammation involves the movement of plasma fluid, containing important proteins such as fibrin and immunoglobulins (antibodies), into inflamed tissue.

Upon contact with PAMPs, tissue macrophages and mastocytes release vasoactive amines such as histamine and serotonin, as well as eicosanoids such as prostaglandin E2 and leukotriene B4 to remodel the local vasculature. ^[27] Macrophages and endothelial cells release nitric oxide. ^[28] These mediators vasodilate and permeabilize the blood vessels, which results in the net distribution of blood plasma from the vessel into the tissue space. The increased collection of fluid into the tissue causes it to swell (edema). ^[27] This exuded tissue fluid contains various antimicrobial mediators from the plasma such as complement, lysozyme, antibodies, which can immediately deal damage to microbes, and opsonise the microbes in preparation for the cellular phase. If the inflammatory stimulus is a lacerating wound, exuded platelets, coagulants, plasmin and kinins can clot the wounded area using vitamin K-dependent mechanisms ^[29] and provide haemostasis in the first instance. These clotting mediators also provide a structural staging framework at the inflammatory tissue site in the form of a fibrin lattice – as would construction scaffolding at a construction site – for the purpose of aiding phagocytic debridement and wound repair later on. Some of the exuded tissue fluid is also funneled by lymphatics to the regional lymph nodes, flushing bacteria along to start the recognition and attack phase of the adaptive immune system.

Infected ingrown toenail showing the characteristic redness and swelling associated with acute inflammation

Acute inflammation is characterized by marked vascular changes, including vasodilation, increased permeability and increased blood flow, which are induced by the actions of various inflammatory mediators. ^[27] Vasodilation occurs first at the arteriole level, progressing to the capillary level, and brings about a net increase in the amount of blood present, causing the redness and heat of inflammation. Increased permeability of the vessels results in the movement of plasma into the tissues, with resultant stasis due to the increase in the concentration of the cells within blood – a condition characterized by enlarged vessels packed with cells. Stasis allows leukocytes to marginate (move) along the endothelium, a process critical to their recruitment into the tissues. Normal flowing blood prevents this, as the shearing force along the periphery of the vessels moves cells in the blood into the middle of the vessel.

Plasma cascade systems

• The complement system, when activated, creates a cascade of chemical reactions that promotes opsonization, chemotaxis, and agglutination, and produces the MAC.
• The kinin system generates proteins capable of sustaining vasodilation and other physical inflammatory effects.
• The coagulation system or clotting cascade, which forms a protective protein mesh over sites of injury.
• The fibrinolysis system, which acts in opposition to the coagulation system, to counterbalance clotting and generate several other inflammatory mediators.

Plasma-derived mediators

* non-exhaustive list

Name	Produced by	Description
Bradykinin	Kinin system	A vasoactive protein that is able to induce vasodilation, increase vascular permeability, cause smooth muscle contraction, and induce pain.
C3	Complement system	Cleaves to produce C3a and C3b. C3a stimulates histamine release by mast cells, thereby producing vasodilation. C3b is able to bind to bacterial cell walls and act as an opsonin, which marks the invader as a target for phagocytosis.
C5a	Complement system	Stimulates histamine release by mast cells, thereby producing vasodilation. It is also able to act as a chemoattractant to direct cells via chemotaxis to the site of inflammation.
Factor XII (Hageman Factor)	Liver	A protein that circulates inactively, until activated by collagen, platelets, or exposed basement membranes via conformational change. When activated, it in turn is able to activate three plasma systems involved in inflammation: the kinin system, fibrinolysis system, and coagulation system.
Membrane attack complex	Complement system	A complex of the complement proteins C5b, C6, C7, C8, and multiple units of C9. The combination and activation of this range of complement proteins forms the membrane attack complex, which is able to insert into bacterial cell walls and causes cell lysis with ensuing bacterial death.
Plasmin	Fibrinolysis system	Able to break down fibrin clots, cleave complement protein C3, and activate Factor XII.
Thrombin	Coagulation system	Cleaves the soluble plasma protein fibrinogen to produce insoluble fibrin, which aggregates to form a blood clot. Thrombin can also bind to cells via the PAR1 receptor to trigger several other inflammatory responses, such as production of chemokines and nitric oxide.

Cellular component

The cellular component involves leukocytes, which normally reside in blood and must move into the inflamed tissue via extravasation to aid in inflammation. ^[25] Some act as phagocytes, ingesting bacteria, viruses, and cellular debris. Others release enzymatic granules that damage pathogenic invaders. Leukocytes also release inflammatory mediators that develop and maintain the inflammatory response. In general, acute inflammation is mediated by granulocytes, whereas chronic inflammation is mediated by mononuclear cells such as monocytes and lymphocytes.

Leukocyte extravasation

Neutrophils migrate from blood vessels to the infected tissue via chemotaxis, where they remove pathogens through phagocytosis and degranulation

Inflammation is a process by which the body's white blood cells and substances they produce protect us from infection with foreign organisms, such as bacteria and viruses. The (phagocytes) white blood cells are a nonspecific immune response, meaning that they attack any foreign bodies. However, in some diseases, like arthritis, the body's defense system the immune system triggers an inflammatory response when there are no foreign invaders to fight off. In these diseases, called autoimmune diseases, the body's normally protective immune system causes damage to its own tissues. The body responds as if normal tissues are infected or somehow abnormal.

Main article: Leukocyte extravasation

Various leukocytes, particularly neutrophils, are critically involved in the initiation and maintenance of inflammation. These cells must be able to move to the site of injury from their usual location in the blood, therefore mechanisms exist to recruit and direct leukocytes to the appropriate place. The process of leukocyte movement from the blood to the tissues through the blood vessels is known as extravasation and can be broadly divided up into a number of steps:

1. Leukocyte margination and endothelial adhesion: The white blood cells within the vessels which are generally centrally located move peripherally towards the walls of the vessels. ^[30] Activated macrophages in the tissue release cytokines such as IL-1 and TNFα, which in turn leads to production of chemokines that bind to proteoglycans forming gradient in the inflamed tissue and along the endothelial wall. ^[27] Inflammatory cytokines induce the immediate expression of P-selectin on endothelial cell surfaces and P-selectin binds weakly to carbohydrate ligands on the surface of leukocytes and causes them to "roll" along the endothelial surface as bonds are made and broken. Cytokines released from injured cells induce the expression of E-selectin on endothelial cells, which functions similarly to P-selectin. Cytokines also induce the expression of integrin ligands such as ICAM-1 and VCAM-1 on endothelial cells, which mediate the adhesion and further slow leukocytes down. These weakly bound leukocytes are free to detach if not activated by chemokines produced in injured tissue after signal transduction via respective G protein-coupled receptors that activates integrins on the leukocyte surface for firm adhesion. Such activation increases the affinity of bound integrin receptors for ICAM-1 and VCAM-1 on the endothelial cell surface, firmly binding the leukocytes to the endothelium.
2. Migration across the endothelium, known as transmigration, via the process of diapedesis: Chemokine gradients stimulate the adhered leukocytes to move between adjacent endothelial cells. The endothelial cells retract and the leukocytes pass through the basement membrane into the surrounding tissue using adhesion molecules such as ICAM-1. ^[30]
3. Movement of leukocytes within the tissue via chemotaxis: Leukocytes reaching the tissue interstitium bind to extracellular matrix proteins via expressed integrins and CD44 to prevent them from leaving the site. A variety of molecules behave as chemoattractants, for example, C3a or C5a (the anaphylatoxins), and cause the leukocytes to move along a chemotactic gradient towards the source of inflammation.

Phagocytosis

Main article: Phagocyte

Extravasated neutrophils in the cellular phase come into contact with microbes at the inflamed tissue. Phagocytes express cell-surface endocytic pattern recognition receptors (PRRs) that have affinity and efficacy against non-specific microbe-associated molecular patterns (PAMPs). Most PAMPs that bind to endocytic PRRs and initiate phagocytosis are cell wall components, including complex carbohydrates such as mannans and β-glucans, lipopolysaccharides (LPS), peptidoglycans, and surface proteins. Endocytic PRRs on phagocytes reflect these molecular patterns, with C-type lectin receptors binding to mannans and β-glucans, and scavenger receptors binding to LPS.

Upon endocytic PRR binding, actin-myosin cytoskeletal rearrangement adjacent to the plasma membrane occurs in a way that endocytoses the plasma membrane containing the PRR-PAMP complex, and the microbe. Phosphatidylinositol and Vps34-Vps15-Beclin1 signalling pathways have been implicated to traffic the endocytosed phagosome to intracellular lysosomes, where fusion of the phagosome and the lysosome produces a phagolysosome. The reactive oxygen species, superoxides and hypochlorite bleach within the phagolysosomes then kill microbes inside the phagocyte.

Phagocytic efficacy can be enhanced by opsonization. Plasma derived complement C3b and antibodies that exude into the inflamed tissue during the vascular phase bind to and coat the microbial antigens. As well as endocytic PRRs, phagocytes also express opsonin receptors Fc receptor and complement receptor 1 (CR1), which bind to antibodies and C3b, respectively. The co-stimulation of endocytic PRR and opsonin receptor increases the efficacy of the phagocytic process, enhancing the lysosomal elimination of the infective agent.

Cell-derived mediators

* non-exhaustive list

Name	Type	Source	Description
Lysosome granules	Enzymes	Granulocytes	These cells contain a large variety of enzymes that perform a number of functions. Granules can be classified as either specific or azurophilic depending upon the contents, and are able to break down a number of substances, some of which may be plasma-derived proteins that allow these enzymes to act as inflammatory mediators.
GM-CSF	Glycoprotein	Macrophages, monocytes, T-cells, B-cells, and tissue-resident cells	Elevated GM-CSF has been shown to contribute to inflammation in inflammatory arthritis, osteoarthritis, colitis asthma, obesity, and COVID-19.
Histamine	Monoamine	Mast cells and basophils	Stored in preformed granules, histamine is released in response to a number of stimuli. It causes arteriole dilation, increased venous permeability, and a wide variety of organ-specific effects.
IFN-γ	Cytokine	T-cells, NK cells	Antiviral, immunoregulatory, and anti-tumour properties. This interferon was originally called macrophage-activating factor, and is especially important in the maintenance of chronic inflammation.
IL-6	Cytokine and Myokine	Macrophages, osteoblasts, adipocytes, and smooth muscle cells (cytokine) Skeletal muscle cells (myokine)	Pro-inflammatory cytokine secreted by macrophages in response to pathogen-associated molecular patterns (PAMPs); pro-inflammatory cytokine secreted by adipocytes, especially in obesity; anti-inflammatory myokine secreted by skeletal muscle cells in response to exercise.
IL-8	Chemokine	Primarily macrophages	Activation and chemoattraction of neutrophils, with a weak effect on monocytes and eosinophils.
Leukotriene B4	Eicosanoid	Leukocytes, cancer cells	Able to mediate leukocyte adhesion and activation, allowing them to bind to the endothelium and migrate across it. In neutrophils, it is also a potent chemoattractant, and is able to induce the formation of reactive oxygen species and the release of lysosomal enzymes by these cells.
LTC4 , LTD4	Eicosanoid	eosinophils, mast cells, macrophages	These three Cysteine-containing leukotrienes contract lung airways, increase micro-vascular permeability, stimulate mucus secretion, and promote eosinophil-based inflammation in the lung, skin, nose, eye, and other tissues.
5-oxo-eicosatetraenoic acid	Eicosanoid	Leukocytes, cancer cells	Potent stimulator of neutrophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation; monocyte chemotaxis; and with even greater potency eosinophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation.
5-HETE	Eicosanoid	Leukocytes	Metabolic precursor to 5-Oxo-eicosatetraenoic acid, it is a less potent stimulator of neutrophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation; monocyte chemotaxis; and eosinophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation.
Prostaglandins	Eicosanoid	Mast cells	A group of lipids that can cause vasodilation, fever, and pain.
Nitric oxide	Soluble gas	Macrophages, endothelial cells, some neurons	Potent vasodilator, relaxes smooth muscle, reduces platelet aggregation, aids in leukocyte recruitment, direct antimicrobial activity in high concentrations.
TNF-α and IL-1	Cytokines	Primarily macrophages	Both affect a wide variety of cells to induce many similar inflammatory reactions: fever, production of cytokines, endothelial gene regulation, chemotaxis, leukocyte adherence, activation of fibroblasts. Responsible for the systemic effects of inflammation, such as loss of appetite and increased heart rate. TNF-α inhibits osteoblast differentiation.
Tryptase	Enzymes	Mast Cells	This serine protease is believed to be exclusively stored in mast cells and secreted, along with histamine, during mast cell activation. [31] [32] [33]

Morphologic patterns

Specific patterns of acute and chronic inflammation are seen during particular situations that arise in the body, such as when inflammation occurs on an epithelial surface, or pyogenic bacteria are involved.

• Granulomatous inflammation: Characterised by the formation of granulomas, they are the result of a limited but diverse number of diseases, which include among others tuberculosis, leprosy, sarcoidosis, and syphilis.
• Fibrinous inflammation: Inflammation resulting in a large increase in vascular permeability allows fibrin to pass through the blood vessels. If an appropriate procoagulative stimulus is present, such as cancer cells, ^[10] a fibrinous exudate is deposited. This is commonly seen in serous cavities, where the conversion of fibrinous exudate into a scar can occur between serous membranes, limiting their function. The deposit sometimes forms a pseudomembrane sheet. During inflammation of the intestine (pseudomembranous colitis), pseudomembranous tubes can be formed.
• Purulent inflammation: Inflammation resulting in large amount of pus, which consists of neutrophils, dead cells, and fluid. Infection by pyogenic bacteria such as staphylococci is characteristic of this kind of inflammation. Large, localised collections of pus enclosed by surrounding tissues are called abscesses.
• Serous inflammation: Characterised by the copious effusion of non-viscous serous fluid, commonly produced by mesothelial cells of serous membranes, but may be derived from blood plasma. Skin blisters exemplify this pattern of inflammation.
• Ulcerative inflammation: Inflammation occurring near an epithelium can result in the necrotic loss of tissue from the surface, exposing lower layers. The subsequent excavation in the epithelium is known as an ulcer.

Disorders

Asthma is considered an inflammatory-mediated disorder. On the right is an inflamed airway due to asthma.

Colitis (inflammation of the colon) caused by Crohn's disease.

Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, as demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. Non-immune diseases with causal origins in inflammatory processes include cancer, atherosclerosis, and ischemic heart disease. ^[10]

Examples of disorders associated with inflammation include:

• Acne vulgaris
• Asthma
• Autoimmune diseases
• Autoinflammatory diseases
• Celiac disease
• Chronic prostatitis
• Colitis
• Diverticulitis
• Familial Mediterranean Fever
• Glomerulonephritis
• Hidradenitis suppurativa
• Hypersensitivities
• Inflammatory bowel diseases
• Interstitial cystitis
• Lichen planus
• Mast Cell Activation Syndrome
• Mastocytosis
• Otitis
• Pelvic inflammatory disease
• Peripheral ulcerative keratitis
• Pneumonia
• Reperfusion injury
• Rheumatic fever
• Rheumatoid arthritis
• Rhinitis
• Sarcoidosis
• Transplant rejection
• Vasculitis

Atherosclerosis

Main article: Atherosclerosis

Atherosclerosis, formerly considered a lipid storage disorder, is now understood as a chronic inflammatory condition involving the arterial walls. ^[34] Research has established a fundamental role for inflammation in mediating all stages of atherosclerosis from initiation through progression and, ultimately, the thrombotic complications from it. ^[34] These new findings reveal links between traditional risk factors like cholesterol levels and the underlying mechanisms of atherogenesis.

Clinical studies have shown that this emerging biology of inflammation in atherosclerosis applies directly to people. ^[34] For instance, elevation in markers of inflammation predicts outcomes of people with acute coronary syndromes, independently of myocardial damage. In addition, low-grade chronic inflammation, as indicated by levels of the inflammatory marker C-reactive protein, prospectively defines risk of atherosclerotic complications, thus adding to prognostic information provided by traditional risk factors, such as LDL levels. ^{[35] [34]}

Moreover, certain treatments that reduce coronary risk also limit inflammation. Notably, lipid-lowering medications such as statins have shown anti-inflammatory effects, which may contribute to their efficacy beyond just lowering LDL levels. ^[36] This emerging understanding of inflammation’s role in atherosclerosis has had significant clinical implications, influencing both risk stratification and therapeutic strategies.

Emerging treatments

Recent developments in the treatment of atherosclerosis have focused on addressing inflammation directly. New anti-inflammatory drugs, such as monoclonal antibodies targeting IL-1β, have been studied in large clinical trials, showing promising results in reducing cardiovascular events. ^[37] These drugs offer a potential new avenue for treatment, particularly for patients who do not respond adequately to statins. However, concerns about long-term safety and cost remain significant barriers to widespread adoption.

Connection to depression

Inflammatory processes can be triggered by negative cognition or their consequences, such as stress, violence, or deprivation. Negative cognition may therefore contribute to inflammation, which in turn can lead to depression. A 2019 meta-analysis found that chronic inflammation is associated with a 30% increased risk of developing major depressive disorder, supporting the link between inflammation and mental health. ^[38]

Allergy

An allergic reaction, formally known as type 1 hypersensitivity, is the result of an inappropriate immune response triggering inflammation, vasodilation, and nerve irritation. A common example is hay fever, which is caused by a hypersensitive response by mast cells to allergens. Pre-sensitised mast cells respond by degranulating, releasing vasoactive chemicals such as histamine. These chemicals propagate an excessive inflammatory response characterised by blood vessel dilation, production of pro-inflammatory molecules, cytokine release, and recruitment of leukocytes. ^[10] Severe inflammatory response may mature into a systemic response known as anaphylaxis.

Myopathies

Inflammatory myopathies are caused by the immune system inappropriately attacking components of muscle, leading to signs of muscle inflammation. They may occur in conjunction with other immune disorders, such as systemic sclerosis, and include dermatomyositis, polymyositis, and inclusion body myositis. ^[10]

Leukocyte defects

Due to the central role of leukocytes in the development and propagation of inflammation, defects in leukocyte functionality often result in a decreased capacity for inflammatory defense with subsequent vulnerability to infection. ^[10] Dysfunctional leukocytes may be unable to correctly bind to blood vessels due to surface receptor mutations, digest bacteria (Chédiak–Higashi syndrome), or produce microbicides (chronic granulomatous disease). In addition, diseases affecting the bone marrow may result in abnormal or few leukocytes.

Pharmacological

Certain drugs or exogenous chemical compounds are known to affect inflammation. Vitamin A deficiency, for example, causes an increase in inflammatory responses, ^[39] and anti-inflammatory drugs work specifically by inhibiting the enzymes that produce inflammatory eicosanoids. Additionally, certain illicit drugs such as cocaine and ecstasy may exert some of their detrimental effects by activating transcription factors intimately involved with inflammation (e.g. NF-κB). ^{[40] [41]}

Cancer

Inflammation orchestrates the microenvironment around tumours, contributing to proliferation, survival and migration. ^[42] Cancer cells use selectins, chemokines and their receptors for invasion, migration and metastasis. ^[43] On the other hand, many cells of the immune system contribute to cancer immunology, suppressing cancer. ^[44] Molecular intersection between receptors of steroid hormones, which have important effects on cellular development, and transcription factors that play key roles in inflammation, such as NF-κB, may mediate some of the most critical effects of inflammatory stimuli on cancer cells. ^[45] This capacity of a mediator of inflammation to influence the effects of steroid hormones in cells is very likely to affect carcinogenesis. On the other hand, due to the modular nature of many steroid hormone receptors, this interaction may offer ways to interfere with cancer progression, through targeting of a specific protein domain in a specific cell type. Such an approach may limit side effects that are unrelated to the tumor of interest, and may help preserve vital homeostatic functions and developmental processes in the organism.

There is some evidence from 2009 to suggest that cancer-related inflammation (CRI) may lead to accumulation of random genetic alterations in cancer cells. ^{[46] [ needs update ]}

Role in cancer

In 1863, Rudolf Virchow hypothesized that the origin of cancer was at sites of chronic inflammation. ^{[43] [47]} As of 2012, chronic inflammation was estimated to contribute to approximately 15% to 25% of human cancers. ^{[47] [48]}

Mediators and DNA damage in cancer

An inflammatory mediator is a messenger that acts on blood vessels and/or cells to promote an inflammatory response. ^[49] Inflammatory mediators that contribute to neoplasia include prostaglandins, inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-15 and chemokines such as IL-8 and GRO-alpha. ^{[50] [47]} These inflammatory mediators, and others, orchestrate an environment that fosters proliferation and survival. ^{[43] [50]}

Inflammation also causes DNA damages due to the induction of reactive oxygen species (ROS) by various intracellular inflammatory mediators. ^{[43] [50] [47]} In addition, leukocytes and other phagocytic cells attracted to the site of inflammation induce DNA damages in proliferating cells through their generation of ROS and reactive nitrogen species (RNS). ROS and RNS are normally produced by these cells to fight infection. ^[43] ROS, alone, cause more than 20 types of DNA damage. ^[51] Oxidative DNA damages cause both mutations ^[52] and epigenetic alterations. ^{[53] [47] [54]} RNS also cause mutagenic DNA damages. ^[55]

A normal cell may undergo carcinogenesis to become a cancer cell if it is frequently subjected to DNA damage during long periods of chronic inflammation. DNA damages may cause genetic mutations due to inaccurate repair. In addition, mistakes in the DNA repair process may cause epigenetic alterations. ^{[47] [50] [54]} Mutations and epigenetic alterations that are replicated and provide a selective advantage during somatic cell proliferation may be carcinogenic.

Genome-wide analyses of human cancer tissues reveal that a single typical cancer cell may possess roughly 100 mutations in coding regions, 10–20 of which are "driver mutations" that contribute to cancer development. ^[47] However, chronic inflammation also causes epigenetic changes such as DNA methylations, that are often more common than mutations. Typically, several hundreds to thousands of genes are methylated in a cancer cell (see DNA methylation in cancer). Sites of oxidative damage in chromatin can recruit complexes that contain DNA methyltransferases (DNMTs), a histone deacetylase (SIRT1), and a histone methyltransferase (EZH2), and thus induce DNA methylation. ^{[47] [56] [57]} DNA methylation of a CpG island in a promoter region may cause silencing of its downstream gene (see CpG site and regulation of transcription in cancer). DNA repair genes, in particular, are frequently inactivated by methylation in various cancers (see hypermethylation of DNA repair genes in cancer). A 2018 report ^[58] evaluated the relative importance of mutations and epigenetic alterations in progression to two different types of cancer. This report showed that epigenetic alterations were much more important than mutations in generating gastric cancers (associated with inflammation). ^[59] However, mutations and epigenetic alterations were of roughly equal importance in generating esophageal squamous cell cancers (associated with tobacco chemicals and acetaldehyde, a product of alcohol metabolism).

HIV and AIDS

It has long been recognized that infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. ^{[60] [61] [62]} A substantial body of evidence implicates chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency. ^{[60] [63]} Many now regard HIV infection not only as an evolving virus-induced immunodeficiency, but also as chronic inflammatory disease. ^[64] Even after the introduction of effective antiretroviral therapy (ART) and effective suppression of viremia in HIV-infected individuals, chronic inflammation persists. Animal studies also support the relationship between immune activation and progressive cellular immune deficiency: SIV sm infection of its natural nonhuman primate hosts, the sooty mangabey, causes high-level viral replication but limited evidence of disease. ^{[65] [66]} This lack of pathogenicity is accompanied by a lack of inflammation, immune activation and cellular proliferation. In sharp contrast, experimental SIV sm infection of rhesus macaque produces immune activation and AIDS-like disease with many parallels to human HIV infection. ^[67]

Delineating how CD4 T cells are depleted and how chronic inflammation and immune activation are induced lies at the heart of understanding HIV pathogenesis—one of the top priorities for HIV research by the Office of AIDS Research, National Institutes of Health. Recent studies demonstrated that caspase-1-mediated pyroptosis, a highly inflammatory form of programmed cell death, drives CD4 T-cell depletion and inflammation by HIV. ^{[68] [69] [70]} These are the two signature events that propel HIV disease progression to AIDS. Pyroptosis appears to create a pathogenic vicious cycle in which dying CD4 T cells and other immune cells (including macrophages and neutrophils) release inflammatory signals that recruit more cells into the infected lymphoid tissues to die. The feed-forward nature of this inflammatory response produces chronic inflammation and tissue injury. ^[71] Identifying pyroptosis as the predominant mechanism that causes CD4 T-cell depletion and chronic inflammation, provides novel therapeutic opportunities, namely caspase-1 which controls the pyroptotic pathway. In this regard, pyroptosis of CD4 T cells and secretion of pro-inflammatory cytokines such as IL-1β and IL-18 can be blocked in HIV-infected human lymphoid tissues by addition of the caspase-1 inhibitor VX-765, ^[68] which has already proven to be safe and well tolerated in phase II human clinical trials. ^[72] These findings could propel development of an entirely new class of "anti-AIDS" therapies that act by targeting the host rather than the virus. Such agents would almost certainly be used in combination with ART. By promoting "tolerance" of the virus instead of suppressing its replication, VX-765 or related drugs may mimic the evolutionary solutions occurring in multiple monkey hosts (e.g. the sooty mangabey) infected with species-specific lentiviruses that have led to a lack of disease, no decline in CD4 T-cell counts, and no chronic inflammation.

Resolution

The inflammatory response must be actively terminated when no longer needed to prevent unnecessary "bystander" damage to tissues. ^[10] Failure to do so results in chronic inflammation, and cellular destruction. Resolution of inflammation occurs by different mechanisms in different tissues. Mechanisms that serve to terminate inflammation include: ^{[10] [73]}

• Short half-life of inflammatory mediators in vivo.
• Production and release of transforming growth factor (TGF) beta from macrophages ^{[74] [75] [76]}
• Production and release of interleukin 10 (IL-10) ^[77]
• Production of anti-inflammatory specialized proresolving mediators, i.e. lipoxins, resolvins, maresins, and neuroprotectins ^{[78] [79]}
• Downregulation of pro-inflammatory molecules, such as leukotrienes.
• Upregulation of anti-inflammatory molecules such as the interleukin 1 receptor antagonist or the soluble tumor necrosis factor receptor (TNFR)
• Apoptosis of pro-inflammatory cells ^[80]
• Desensitization of receptors.
• Increased survival of cells in regions of inflammation due to their interaction with the extracellular matrix (ECM) ^{[81] [82]}
• Downregulation of receptor activity by high concentrations of ligands
• Cleavage of chemokines by matrix metalloproteinases (MMPs) might lead to production of anti-inflammatory factors. ^[83]

Acute inflammation normally resolves by mechanisms that have remained somewhat elusive. Emerging evidence now suggests that an active, coordinated program of resolution initiates in the first few hours after an inflammatory response begins. After entering tissues, granulocytes promote the switch of arachidonic acid–derived prostaglandins and leukotrienes to lipoxins, which initiate the termination sequence. Neutrophil recruitment thus ceases and programmed death by apoptosis is engaged. These events coincide with the biosynthesis, from omega-3 polyunsaturated fatty acids, of resolvins and protectins, which critically shorten the period of neutrophil infiltration by initiating apoptosis. As a consequence, apoptotic neutrophils undergo phagocytosis by macrophages, leading to neutrophil clearance and release of anti-inflammatory and reparative cytokines such as transforming growth factor-β1. The anti-inflammatory program ends with the departure of macrophages through the lymphatics. ^[84]

—  Charles N. Serhan

Connection to depression

There is evidence for a link between inflammation and depression. ^[85] Inflammatory processes can be triggered by negative cognitions or their consequences, such as stress, violence, or deprivation. Thus, negative cognitions can cause inflammation that can, in turn, lead to depression. ^{[86] [87] [ dubious – discuss ]} In addition, there is increasing evidence that inflammation can cause depression because of the increase of cytokines, setting the brain into a "sickness mode". ^[88]

Classical symptoms of being physically sick, such as lethargy, show a large overlap in behaviors that characterize depression. Levels of cytokines tend to increase sharply during the depressive episodes of people with bipolar disorder and drop off during remission. ^[89] Furthermore, it has been shown in clinical trials that anti-inflammatory medicines taken in addition to antidepressants not only significantly improves symptoms but also increases the proportion of subjects positively responding to treatment. ^[90] Inflammations that lead to serious depression could be caused by common infections such as those caused by a virus, bacteria or even parasites. ^[91]

Connection to delirium

There is evidence for a link between inflammation and delirium based on the results of a recent longitudinal study investigating CRP in COVID-19 patients. ^[92]

Systemic effects

An infectious organism can escape the confines of the immediate tissue via the circulatory system or lymphatic system, where it may spread to other parts of the body. If an organism is not contained by the actions of acute inflammation, it may gain access to the lymphatic system via nearby lymph vessels. An infection of the lymph vessels is known as lymphangitis, and infection of a lymph node is known as lymphadenitis. When lymph nodes cannot destroy all pathogens, the infection spreads further. A pathogen can gain access to the bloodstream through lymphatic drainage into the circulatory system.

When inflammation overwhelms the host, systemic inflammatory response syndrome is diagnosed. When it is due to infection, the term sepsis is applied, with the terms bacteremia being applied specifically for bacterial sepsis and viremia specifically to viral sepsis. Vasodilation and organ dysfunction are serious problems associated with widespread infection that may lead to septic shock and death. ^[93]

Acute-phase proteins

Inflammation also is characterized by high systemic levels of acute-phase proteins. In acute inflammation, these proteins prove beneficial; however, in chronic inflammation, they can contribute to amyloidosis. ^[10] These proteins include C-reactive protein, serum amyloid A, and serum amyloid P, which cause a range of systemic effects including: ^[10]

• Fever
• Increased blood pressure
• Decreased sweating
• Malaise
• Loss of appetite
• Somnolence

Leukocyte numbers

Inflammation often affects the numbers of leukocytes present in the body:

• Leukocytosis is often seen during inflammation induced by infection, where it results in a large increase in the amount of leukocytes in the blood, especially immature cells. Leukocyte numbers usually increase to between 15 000 and 20 000 cells per microliter, but extreme cases can see it approach 100 000 cells per microliter. ^[10] Bacterial infection usually results in an increase of neutrophils, creating neutrophilia, whereas diseases such as asthma, hay fever, and parasite infestation result in an increase in eosinophils, creating eosinophilia. ^[10]
• Leukopenia can be induced by certain infections and diseases, including viral infection, Rickettsia infection, some protozoa, tuberculosis, and some cancers. ^[10]

Interleukins and obesity

With the discovery of interleukins (IL), the concept of systemic inflammation developed. Although the processes involved are identical to tissue inflammation, systemic inflammation is not confined to a particular tissue but involves the endothelium and other organ systems.

Chronic inflammation is widely observed in obesity. ^{[94] [95]} Obese people commonly have many elevated markers of inflammation, including: ^{[96] [97]}

• IL-6 (Interleukin-6) ^{[98] [99]}

• IL-8 (Interleukin-8)
• IL-18 (Interleukin-18) ^{[98] [99]}
• TNF-α (Tumor necrosis factor-alpha) ^{[98] [99]}
• CRP (C-reactive protein) ^{[98] [99]}
• Insulin ^{[98] [99]}
• Blood glucose ^{[98] [99]}
• Leptin ^{[98] [99]}

Low-grade chronic inflammation is characterized by a two- to threefold increase in the systemic concentrations of cytokines such as TNF-α, IL-6, and CRP. ^[100] Waist circumference correlates significantly with systemic inflammatory response. ^[101]

Loss of white adipose tissue reduces levels of inflammation markers. ^[94] As of 2017 the association of systemic inflammation with insulin resistance and type 2 diabetes, and with atherosclerosis was under preliminary research, although rigorous clinical trials had not been conducted to confirm such relationships. ^[102]

C-reactive protein (CRP) is generated at a higher level in obese people, and may increase the risk for cardiovascular diseases. ^[103]

Outcomes

The outcome in a particular circumstance will be determined by the tissue in which the injury has occurred—and the injurious agent that is causing it. Here are the possible outcomes to inflammation: ^[10]

1. Resolution
   The complete restoration of the inflamed tissue back to a normal status. Inflammatory measures such as vasodilation, chemical production, and leukocyte infiltration cease, and damaged parenchymal cells regenerate. Such is usually the outcome when limited or short-lived inflammation has occurred.
2. Fibrosis
   Large amounts of tissue destruction, or damage in tissues unable to regenerate, cannot be regenerated completely by the body. Fibrous scarring occurs in these areas of damage, forming a scar composed primarily of collagen. The scar will not contain any specialized structures, such as parenchymal cells, hence functional impairment may occur.
3. Abscess formation
   A cavity is formed containing pus, an opaque liquid containing dead white blood cells and bacteria with general debris from destroyed cells.
4. Chronic inflammation
   In acute inflammation, if the injurious agent persists then chronic inflammation will ensue. This process, marked by inflammation lasting many days, months or even years, may lead to the formation of a chronic wound. Chronic inflammation is characterised by the dominating presence of macrophages in the injured tissue. These cells are powerful defensive agents of the body, but the toxins they release—including reactive oxygen species—are injurious to the organism's own tissues as well as invading agents. As a consequence, chronic inflammation is almost always accompanied by tissue destruction.

Examples

Inflammation is usually indicated by adding the suffix "itis", as shown below. However, some conditions, such as asthma and pneumonia, do not follow this convention. More examples are available at List of types of inflammation.

• 
  Acute appendicitis
• 
  Acute dermatitis
• 
  Acute infective meningitis
• 
  Acute tonsillitis

See also

• Anaphylatoxin
• Anti-inflammatories
• Essential fatty acid interactions
• Healing
• Inflammaging
• Inflammatory cytokine
• Inflammatory reflex
• Interleukin
• Lipoxin
• Neurogenic inflammation
• Substance P
• Stress (biology)
• Endothelial Cell Tropism

Notes

1. All these signs may be observed in specific instances, but no single sign must, as a matter of course, be present. ^[14] These are the original, or cardinal signs of inflammation. ^[14]
2. Functio laesa is an antiquated notion, as it is not unique to inflammation and is a characteristic of many disease states. ^[15]

References

1. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE (February 2007). "Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation". Clinical and Experimental Immunology. 147 (2): 227–235. doi:10.1111/j.1365-2249.2006.03261.x. PMC   1810472 . PMID   17223962.
2. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. (January 2018). "Inflammatory responses and inflammation-associated diseases in organs". Oncotarget. 9 (6). Impact Journals, LLC: 7204–7218. doi:10.18632/oncotarget.23208. PMC   5805548 . PMID   29467962. S2CID   3571245.
3. Abbas AB, Lichtman AH (2009). "Ch.2 Innate Immunity". Basic Immunology. Functions and disorders of the immune system (3rd ed.). Saunders/Elsevier. ISBN   978-1-4160-4688-2.
4. "Inflammation and Your Health". Cedars-Sinai.
5. Berger A (August 2000). "Th1 and Th2 responses: what are they?". BMJ. 321 (7258): 424. doi:10.1136/bmj.321.7258.424. PMC   27457 . PMID   10938051. Archived from the original on 12 July 2021. Retrieved 1 July 2021.
6. "inflammation". Etymology of inflammation by etymonline. 28 September 2017. Retrieved 11 August 2024.
7. Hall J (2011). Guyton and Hall textbook of medical physiology (12th ed.). Philadelphia, Pa.: Saunders/Elsevier. p. 428. ISBN   978-1-4160-4574-8.
8. Granger DN, Senchenkova E (2010). "Leukocyte–Endothelial Cell Adhesion". Inflammation and the Microcirculation. Integrated Systems Physiology—From Cell to Function. Vol. 2. Morgan & Claypool Life Sciences. pp. 1–87. doi:10.4199/C00013ED1V01Y201006ISP008. PMID   21452440. Archived from the original on 21 January 2021. Retrieved 1 July 2017.
9. Piira OP, Miettinen JA, Hautala AJ, Huikuri HV, Tulppo MP (October 2013). "Physiological responses to emotional excitement in healthy subjects and patients with coronary artery disease". Autonomic Neuroscience. 177 (2): 280–5. doi:10.1016/j.autneu.2013.06.001. PMID   23916871. S2CID   19823098.
10. Robbins SL, Cotran RS, Kumar V, Collins T (1998). Robbins Pathologic Basis of Disease. Philadelphia: W.B Saunders Company. ISBN   978-0-7216-7335-6.
11. Kumar R, Clermont G, Vodovotz Y, Chow CC (September 2004). "The dynamics of acute inflammation". Journal of Theoretical Biology. 230 (2): 145–55. arXiv: q-bio/0404034 . Bibcode:2004PhDT.......405K. doi:10.1016/j.jtbi.2004.04.044. PMID   15321710. S2CID   16992741.
12. Hannoodee S, Nasuruddin DN (2020). "Acute Inflammatory Response". StatPearls . PMID   32310543. Archived from the original on 15 June 2022. Retrieved 28 December 2020.
13. Pahwa R, Goyal A, Bansal P, Jialal I (28 September 2021). "Chronic Inflammation". StatPearls . National Institutes of Health – National Library of Medicine. PMID   29630225. Archived from the original on 19 December 2020. Retrieved 28 December 2020.
14. Stedman's Medical Dictionary (Twenty-fifth ed.). Williams & Wilkins. 1990.
15. Rather LJ (March 1971). "Disturbance of function (functio laesa): the legendary fifth cardinal sign of inflammation, added by Claudius Galen to the four cardinal signs of Celsus". Bulletin of the New York Academy of Medicine. 47 (3): 303–22. PMC   1749862 . PMID   5276838.
16. Chandrasoma P, Taylor CR (2005). "Part A. "General Pathology", Section II. "The Host Response to Injury", Chapter 3. "The Acute Inflammatory Response", sub-section "Cardinal Clinical Signs"". Concise Pathology (3rd ed.). McGraw-Hill. ISBN   978-0-8385-1499-3. OCLC   150148447. Archived from the original on 5 October 2008. Retrieved 5 November 2008.
17. Rather LJ (March 1971). "Disturbance of function (functio laesa): the legendary fifth cardinal sign of inflammation, added by Galen to the four cardinal signs of Celsus". Bulletin of the New York Academy of Medicine. 47 (3): 303–322. PMC   1749862 . PMID   5276838.
18. Werner R (2009). A massage Therapist Guide to Pathology (4th ed.). Wolters Kluwer. ISBN   978-0-7817-6919-8. Archived from the original on 21 December 2015. Retrieved 6 October 2010.
19. Vogel WH, Berke A (2009). Brief History of Vision and Ocular Medicine. Kugler Publications. p. 97. ISBN   978-90-6299-220-1.
20. Porth C (2007). Essentials of pahtophysiology: concepts of altered health states. Hagerstown, MD: Lippincott Williams & Wilkins. p. 270. ISBN   978-0-7817-7087-3.
21. Dormandy T (2006). The worst of evils: man's fight against pain . New Haven, Conn: Yale University Press. pp.  22. ISBN   978-0-300-11322-8.
22. InformedHealth.org [Internet]. Institute for Quality and Efficiency in Health Care (IQWiG). 22 February 2018 – via www.ncbi.nlm.nih.gov.
23. "Inflammation | Definition, Symptoms, Treatment, & Facts | Britannica". www.britannica.com. 11 March 2024.
24. Robbins S, Cotran R, Kumar V, Abbas A, Aster J (2020). Pathologic basis of disease (10th ed.). Philadelphia, PA: Saunders Elsevier.
25. Raiten DJ, Sakr Ashour FA, Ross AC, Meydani SN, Dawson HD, Stephensen CB, et al. (May 2015). "Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE)". The Journal of Nutrition. 145 (5): 1039S–1108S. doi:10.3945/jn.114.194571. PMC   4448820 . PMID   25833893.
26. Taams LS (July 2018). "Inflammation and immune resolution". Clinical and Experimental Immunology. 193 (1): 1–2. doi:10.1111/cei.13155. PMC   6037995 . PMID   29987840.
27. Medzhitov R (July 2008). "Origin and physiological roles of inflammation". Nature. 454 (7203): 428–435. Bibcode:2008Natur.454..428M. doi:10.1038/nature07201. PMID   18650913. S2CID   205214291.
28. Mantovani A, Garlanda C (February 2023). Longo DL (ed.). "Humoral Innate Immunity and Acute-Phase Proteins". The New England Journal of Medicine. 388 (5): 439–452. doi:10.1056/NEJMra2206346. PMC   9912245 . PMID   36724330.
29. Ferland G (2020). "Vitamin K". Present Knowledge in Nutrition. Elsevier. pp. 137–153. doi:10.1016/b978-0-323-66162-1.00008-1. ISBN   978-0-323-66162-1 . Retrieved 17 February 2023.
30. Herrington S (2014). Muir's Textbook of Pathology (15th ed.). CRC Press. p. 59. ISBN   978-1-4441-8499-0.
31. Carstens E, Akiyama T, Cevikbas F, Kempkes C, Buhl T, Mess C, et al. (2014). "Role of Interleukin-31 and Oncostatin M in Itch and Neuroimmune Communication". In Carstens M, Akiyama T (eds.). Itch: Mechanisms and Treatment. Frontiers in Neuroscience. Boca Raton (FL): CRC Press/Taylor & Francis. ISBN   978-1-4665-0543-8. PMID   24830021.
32. Caughey GH (June 2007). "Mast cell tryptases and chymases in inflammation and host defense". Immunological Reviews. 217 (1): 141–54. doi:10.1111/j.1600-065x.2007.00509.x. PMC   2275918 . PMID   17498057.
33. Caughey GH (May 2016). "Mast cell proteases as pharmacological targets". European Journal of Pharmacology. Pharmacological modulation of Mast cells and Basophils. 778: 44–55. doi:10.1016/j.ejphar.2015.04.045. PMC   4636979 . PMID   25958181.
34. Libby P (November 2021). "Inflammation during the life cycle of the atherosclerotic plaque". Cardiovascular Research. 117 (13): 2525–2536. doi:10.1093/cvr/cvab303. PMC   8783385 . PMID   34550337.
35. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A (November 2007). "Role of inflammation in atherosclerosis". Journal of Nuclear Medicine. 48 (11): 1800–1815. doi:10.2967/jnumed.107.038661. PMID   17942804.
36. Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, et al. (January 2022). "Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer". Pharmaceuticals. 15 (2): 151. doi: 10.3390/ph15020151 . PMC   8877351 . PMID   35215263.
37. Szekely Y, Arbel Y (June 2018). "A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?". Cardiology and Therapy. 7 (1): 25–44. doi:10.1007/s40119-018-0104-3. PMC   5986669 . PMID   29417406.
38. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD (July 2020). "Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls". Brain, Behavior, and Immunity. 87: 901–909. doi:10.1016/j.bbi.2020.02.010. PMC   7327519 . PMID   32113908.
39. Wiedermann U, Chen XJ, Enerbäck L, Hanson LA, Kahu H, Dahlgren UI (December 1996). "Vitamin A deficiency increases inflammatory responses". Scandinavian Journal of Immunology. 44 (6): 578–84. doi:10.1046/j.1365-3083.1996.d01-351.x. PMID   8972739. S2CID   3079540.
40. Hargrave BY, Tiangco DA, Lattanzio FA, Beebe SJ (2003). "Cocaine, not morphine, causes the generation of reactive oxygen species and activation of NF-kappaB in transiently cotransfected heart cells". Cardiovascular Toxicology. 3 (2): 141–51. doi:10.1385/CT:3:2:141. PMID   14501032. S2CID   35240781.
41. Montiel-Duarte C, Ansorena E, López-Zabalza MJ, Cenarruzabeitia E, Iraburu MJ (March 2004). "Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine ("Ecstasy") on hepatic stellate cells". Biochemical Pharmacology. 67 (6): 1025–33. doi:10.1016/j.bcp.2003.10.020. PMID   15006539.
42. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R (September 2011). "Interaction of tumor cells with the microenvironment". Cell Communication and Signaling. 9: 18. doi: 10.1186/1478-811X-9-18 . PMC   3180438 . PMID   21914164.
43. Coussens LM, Werb Z (2002). "Inflammation and cancer". Nature. 420 (6917): 860–7. Bibcode:2002Natur.420..860C. doi:10.1038/nature01322. PMC   2803035 . PMID   12490959.
44. Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y, et al. (September 2012). "Opposing roles for complement component C5a in tumor progression and the tumor microenvironment". Journal of Immunology. 189 (6): 2985–94. doi:10.4049/jimmunol.1200846. PMC   3436956 . PMID   22914051.
45. Copland JA, Sheffield-Moore M, Koldzic-Zivanovic N, Gentry S, Lamprou G, Tzortzatou-Stathopoulou F, et al. (June 2009). "Sex steroid receptors in skeletal differentiation and epithelial neoplasia: is tissue-specific intervention possible?". BioEssays. 31 (6): 629–41. doi:10.1002/bies.200800138. PMID   19382224. S2CID   205469320.
46. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (July 2009). "Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability". Carcinogenesis (review). 30 (7): 1073–81. doi: 10.1093/carcin/bgp127 . PMID   19468060.
47. Chiba T, Marusawa H, Ushijima T (September 2012). "Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation" (PDF). Gastroenterology. 143 (3): 550–563. doi:10.1053/j.gastro.2012.07.009. hdl: 2433/160134 . PMID   22796521. S2CID   206226588. Archived (PDF) from the original on 29 August 2022. Retrieved 9 June 2018.
48. Mantovani A, Allavena P, Sica A, Balkwill F (July 2008). "Cancer-related inflammation" (PDF). Nature. 454 (7203): 436–44. Bibcode:2008Natur.454..436M. doi:10.1038/nature07205. hdl: 2434/145688 . PMID   18650914. S2CID   4429118. Archived (PDF) from the original on 30 October 2022. Retrieved 9 June 2018.
49. Larsen GL, Henson PM (1983). "Mediators of inflammation". Annual Review of Immunology. 1: 335–59. doi:10.1146/annurev.iy.01.040183.002003. PMID   6399978.
50. Shacter E, Weitzman SA (February 2002). "Chronic inflammation and cancer". Oncology. 16 (2): 217–26, 229, discussion 230–2. PMID   11866137.
51. Yu Y, Cui Y, Niedernhofer LJ, Wang Y (December 2016). "Occurrence, Biological Consequences, and Human Health Relevance of Oxidative Stress-Induced DNA Damage". Chemical Research in Toxicology. 29 (12): 2008–2039. doi:10.1021/acs.chemrestox.6b00265. PMC   5614522 . PMID   27989142.
52. Dizdaroglu M (December 2012). "Oxidatively induced DNA damage: mechanisms, repair and disease". Cancer Letters. 327 (1–2): 26–47. doi:10.1016/j.canlet.2012.01.016. PMID   22293091.
53. Nishida N, Kudo M (2013). "Oxidative stress and epigenetic instability in human hepatocarcinogenesis". Digestive Diseases. 31 (5–6): 447–53. doi: 10.1159/000355243 . PMID   24281019.
54. Ding N, Maiuri AR, O'Hagan HM (2017). "The emerging role of epigenetic modifiers in repair of DNA damage associated with chronic inflammatory diseases". Mutation Research. 780: 69–81. doi:10.1016/j.mrrev.2017.09.005. PMC   6690501 . PMID   31395351.
55. Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Oikawa S, Murata M (2016). "Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells". Genes and Environment. 38 (1): 26. Bibcode:2016GeneE..38...26K. doi: 10.1186/s41021-016-0055-7 . PMC   5203929 . PMID   28050219.
56. O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, et al. (November 2011). "Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands". Cancer Cell. 20 (5): 606–19. doi:10.1016/j.ccr.2011.09.012. PMC   3220885 . PMID   22094255.
57. Maiuri AR, Peng M, Podicheti R, Sriramkumar S, Kamplain CM, Rusch DB, et al. (July 2017). "Mismatch Repair Proteins Initiate Epigenetic Alterations during Inflammation-Driven Tumorigenesis". Cancer Research. 77 (13): 3467–3478. doi:10.1158/0008-5472.CAN-17-0056. PMC   5516887 . PMID   28522752.
58. Yamashita S, Kishino T, Takahashi T, Shimazu T, Charvat H, Kakugawa Y, et al. (February 2018). "Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues". Proceedings of the National Academy of Sciences of the United States of America. 115 (6): 1328–1333. Bibcode:2018PNAS..115.1328Y. doi: 10.1073/pnas.1717340115 . PMC   5819434 . PMID   29358395.
59. Raza Y, Khan A, Farooqui A, Mubarak M, Facista A, Akhtar SS, et al. (October 2014). "Oxidative DNA damage as a potential early biomarker of Helicobacter pylori associated carcinogenesis". Pathology & Oncology Research. 20 (4): 839–46. doi:10.1007/s12253-014-9762-1. PMID   24664859. S2CID   18727504.
60. Deeks SG (1 January 2011). "HIV infection, inflammation, immunosenescence, and aging". Annual Review of Medicine. 62: 141–55. doi:10.1146/annurev-med-042909-093756. PMC   3759035 . PMID   21090961.
61. Klatt NR, Chomont N, Douek DC, Deeks SG (July 2013). "Immune activation and HIV persistence: implications for curative approaches to HIV infection". Immunological Reviews. 254 (1): 326–42. doi:10.1111/imr.12065. PMC   3694608 . PMID   23772629.
62. Salazar-Gonzalez JF, Martinez-Maza O, Nishanian P, Aziz N, Shen LP, Grosser S, et al. (August 1998). "Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection". The Journal of Infectious Diseases. 178 (2): 423–30. doi: 10.1086/515629 . PMID   9697722.
63. Ipp H, Zemlin A (February 2013). "The paradox of the immune response in HIV infection: when inflammation becomes harmful". Clinica Chimica Acta; International Journal of Clinical Chemistry. 416: 96–9. doi:10.1016/j.cca.2012.11.025. PMID   23228847.
64. Nasi M, Pinti M, Mussini C, Cossarizza A (October 2014). "Persistent inflammation in HIV infection: established concepts, new perspectives". Immunology Letters. 161 (2): 184–8. doi:10.1016/j.imlet.2014.01.008. PMID   24487059.
65. Milush JM, Mir KD, Sundaravaradan V, Gordon SN, Engram J, Cano CA, et al. (March 2011). "Lack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4+ T cell loss is associated with double-negative T cells". The Journal of Clinical Investigation. 121 (3): 1102–10. doi:10.1172/JCI44876. PMC   3049370 . PMID   21317533.
66. Rey-Cuillé MA, Berthier JL, Bomsel-Demontoy MC, Chaduc Y, Montagnier L, Hovanessian AG, et al. (May 1998). "Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease". Journal of Virology. 72 (5): 3872–86. doi:10.1128/JVI.72.5.3872-3886.1998. PMC   109612 . PMID   9557672.
67. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G (March 2012). "Natural SIV hosts: showing AIDS the door". Science. 335 (6073): 1188–93. Bibcode:2012Sci...335.1188C. doi:10.1126/science.1217550. PMC   3822437 . PMID   22403383.
68. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. (January 2014). "Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection". Nature. 505 (7484): 509–14. Bibcode:2014Natur.505..509D. doi:10.1038/nature12940. PMC   4047036 . PMID   24356306.
69. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, et al. (January 2014). "IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV". Science. 343 (6169): 428–32. Bibcode:2014Sci...343..428M. doi:10.1126/science.1243640. PMC   3976200 . PMID   24356113.
70. Galloway NL, Doitsh G, Monroe KM, Yang Z, Muñoz-Arias I, Levy DN, et al. (September 2015). "Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-Derived CD4 T Cells". Cell Reports. 12 (10): 1555–1563. doi:10.1016/j.celrep.2015.08.011. PMC   4565731 . PMID   26321639.
71. Doitsh G, Greene WC (March 2016). "Dissecting How CD4 T Cells Are Lost During HIV Infection". Cell Host & Microbe. 19 (3): 280–91. doi:10.1016/j.chom.2016.02.012. PMC   4835240 . PMID   26962940.
72. "Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy – Full Text View – ClinicalTrials.gov". clinicaltrials.gov. 19 December 2013. Archived from the original on 26 September 2022. Retrieved 21 May 2016.
73. Eming SA, Krieg T, Davidson JM (March 2007). "Inflammation in wound repair: molecular and cellular mechanisms". The Journal of Investigative Dermatology. 127 (3): 514–25. doi: 10.1038/sj.jid.5700701 . PMID   17299434.
74. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, et al. (September 1999). "Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response". Nature Cell Biology. 1 (5): 260–6. doi:10.1038/12971. PMID   10559937. S2CID   37216623.
75. Ashcroft GS (December 1999). "Bidirectional regulation of macrophage function by TGF-beta". Microbes and Infection. 1 (15): 1275–82. doi:10.1016/S1286-4579(99)00257-9. PMID   10611755. Archived from the original on 10 January 2020. Retrieved 11 September 2019.
76. Werner F, Jain MK, Feinberg MW, Sibinga NE, Pellacani A, Wiesel P, et al. (November 2000). "Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3". The Journal of Biological Chemistry. 275 (47): 36653–8. doi: 10.1074/jbc.M004536200 . PMID   10973958.
77. Sato Y, Ohshima T, Kondo T (November 1999). "Regulatory role of endogenous interleukin-10 in cutaneous inflammatory response of murine wound healing". Biochemical and Biophysical Research Communications. 265 (1): 194–9. doi:10.1006/bbrc.1999.1455. PMID   10548513.
78. Serhan CN (August 2008). "Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators". Journal of Periodontology. 79 (8 Suppl): 1520–6. doi:10.1902/jop.2008.080231. PMID   18673006.
79. Headland SE, Norling LV (May 2015). "The resolution of inflammation: Principles and challenges". Seminars in Immunology. 27 (3): 149–60. doi:10.1016/j.smim.2015.03.014. PMID   25911383.
80. Greenhalgh DG (September 1998). "The role of apoptosis in wound healing". The International Journal of Biochemistry & Cell Biology. 30 (9): 1019–30. doi:10.1016/S1357-2725(98)00058-2. PMID   9785465.
81. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. (November 2005). "Regulation of lung injury and repair by Toll-like receptors and hyaluronan". Nature Medicine. 11 (11): 1173–9. doi:10.1038/nm1315. PMID   16244651. S2CID   11765495.
82. Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Puré E, et al. (April 2002). "Resolution of lung inflammation by CD44". Science. 296 (5565): 155–8. Bibcode:2002Sci...296..155T. doi:10.1126/science.1069659. PMID   11935029. S2CID   7905603.
83. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM (August 2000). "Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3". Science. 289 (5482): 1202–6. Bibcode:2000Sci...289.1202M. doi:10.1126/science.289.5482.1202. PMID   10947989.
84. Serhan CN, Savill J (December 2005). "Resolution of inflammation: the beginning programs the end". Nature Immunology. 6 (12): 1191–7. doi:10.1038/ni1276. PMID   16369558. S2CID   22379843.
85. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, et al. (September 2013). "So depression is an inflammatory disease, but where does the inflammation come from?". BMC Medicine. 11: 200. doi: 10.1186/1741-7015-11-200 . PMC   3846682 . PMID   24228900.
86. Cox WT, Abramson LY, Devine PG, Hollon SD (September 2012). "Stereotypes, Prejudice, and Depression: The Integrated Perspective". Perspectives on Psychological Science. 7 (5): 427–49. doi:10.1177/1745691612455204. PMID   26168502. S2CID   1512121.
87. Kiecolt-Glaser JK, Derry HM, Fagundes CP (November 2015). "Inflammation: depression fans the flames and feasts on the heat". The American Journal of Psychiatry. 172 (11): 1075–91. doi:10.1176/appi.ajp.2015.15020152. PMC   6511978 . PMID   26357876.
88. Williams C (4 January 2015). "Is depression a kind of allergic reaction?". The Guardian. Archived from the original on 21 October 2022. Retrieved 11 December 2016.
89. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, et al. (August 2009). "Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder". Journal of Affective Disorders. 116 (3): 214–7. doi:10.1016/j.jad.2008.12.001. PMID   19251324.
90. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, et al. (July 2006). "The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine". Molecular Psychiatry. 11 (7): 680–4. doi: 10.1038/sj.mp.4001805 . PMID   16491133.
91. Canli T (2014). "Reconceptualizing major depressive disorder as an infectious disease". Biology of Mood & Anxiety Disorders. 4: 10. doi: 10.1186/2045-5380-4-10 . PMC   4215336 . PMID   25364500.
92. Saini A, Oh TH, Ghanem DA, Castro M, Butler M, Sin Fai Lam CC, et al. (October 2022). "Inflammatory and blood gas markers of COVID-19 delirium compared to non-COVID-19 delirium: a cross-sectional study". Aging & Mental Health. 26 (10): 2054–2061. doi: 10.1080/13607863.2021.1989375 . PMID   34651536. S2CID   238990849. Archived from the original on 22 October 2021. Retrieved 20 February 2023.
93. Ramanlal R, Gupta V (2021). "Physiology, Vasodilation". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   32491494. Archived from the original on 11 May 2021. Retrieved 22 September 2021.
94. Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, Lefebvre d'Hellencourt C (March 2016). "Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research". Journal of Neuroinflammation (Review). 13 (1): 67. doi: 10.1186/s12974-016-0530-x . PMC   4806498 . PMID   27012931.
95. Kershaw EE, Flier JS (June 2004). "Adipose tissue as an endocrine organ". The Journal of Clinical Endocrinology and Metabolism. 89 (6): 2548–56. doi: 10.1210/jc.2004-0395 . PMID   15181022.
96. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. (September 2000). "Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss". The Journal of Clinical Endocrinology and Metabolism. 85 (9): 3338–42. doi: 10.1210/jcem.85.9.6839 . PMID   10999830.
97. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE, et al. (December 2001). "beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies". The Journal of Clinical Endocrinology and Metabolism. 86 (12): 5864–9. doi: 10.1210/jcem.86.12.8104 . PMID   11739453. S2CID   73100391.
98. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. (January 1998). "Leptin regulates proinflammatory immune responses". FASEB Journal. 12 (1): 57–65. doi: 10.1096/fasebj.12.1.57 . PMID   9438411.
99. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. (October 2002). "Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress". Circulation. 106 (16): 2067–72. doi: 10.1161/01.CIR.0000034509.14906.AE . PMID   12379575.
100. Petersen AM, Pedersen BK (April 2005). "The anti-inflammatory effect of exercise". Journal of Applied Physiology. 98 (4): 1154–62. doi:10.1152/japplphysiol.00164.2004. PMID   15772055. S2CID   4776835.
101. Rogowski O, Shapira I, Bassat OK, Chundadze T, Finn T, Berliner S, et al. (July 2010). "Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional study". Journal of Inflammation. 7: 35. doi: 10.1186/1476-9255-7-35 . PMC   2919526 . PMID   20659330.
102. Goldfine AB, Shoelson SE (January 2017). "Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk". The Journal of Clinical Investigation. 127 (1): 83–93. doi: 10.1172/jci88884 . PMC   5199685 . PMID   28045401.
103. Choi J, Joseph L, Pilote L (March 2013). "Obesity and C-reactive protein in various populations: a systematic review and meta-analysis". Obesity Reviews. 14 (3): 232–44. doi:10.1111/obr.12003. PMID   23171381. S2CID   206227739.

External links

• Inflammation at the U.S. National Library of Medicine Medical Subject Headings (MeSH)